A Covid-19 Milestone Attained — A Correlate of Protection for Vaccines | NEJM
Understanding which IBR vaccine to use in your herd
BHV-1: New Molecular Approaches to Control a Common and Widespread Infection | Molecular Medicine | Full Text
COVID-19 vaccine mRNA-1273 elicits a protective immune profile in mice that is not associated with vaccine-enhanced disease upon SARS-CoV-2 challenge - ScienceDirect
Covid-19 Breakthrough Infections in Vaccinated Health Care Workers | NEJM
Glycosite-deleted mRNA of SARS-CoV-2 spike protein as a broad-spectrum vaccine | PNAS
Experiences With Two BHVl Marker-Vaccines
Designing spatial and temporal control of vaccine responses | Nature Reviews Materials
Vaccine - Wikipedia
Disparities in COVID-19 Vaccination Coverage Between Urban and Rural Counties — United States, December 14, 2020–April 10, 2021 | MMWR
Frontiers | Novel Vaccine Technologies in Veterinary Medicine: A Herald to Human Medicine Vaccines
marker vaccine - List of Frontiers' open access articles
HIPRA presented three posters demonstrating its ruminant vaccines' efficacy under field conditions | HIPRA
A Comprehensive Review of the Global Efforts on COVID-19 Vaccine Development | ACS Central Science
Rispoval IBR Marker Inactivated - VetMedicinesDirect
Systemic IL-15, IFN-γ, and IP-10/CXCL10 signature associated with effective immune response to SARS-CoV-2 in BNT162b2 mRNA vaccine recipients - ScienceDirect
Bovine alphaherpesvirus 1 (BoHV-1) gE-deleted marker vaccines used in... | Download Scientific Diagram
Infectious bovine rhinotracheitis (IBR) marker vaccines available in... | Download Table
B and T cell response to SARS-CoV-2 vaccination in health care professionals with and without previous COVID-19 - eBioMedicine
Adverse effects of COVID-19 mRNA vaccines: the spike hypothesis: Trends in Molecular Medicine
PDF) An inactivated gE-negative marker vaccine and an experimental gD-subunit vaccine reduce the incidence of bovine herpesvirus 1 infections in the field | Jan van Oirschot - Academia.edu
Development of an inactivated vaccine candidate for SARS-CoV-2 | Science
